Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by Donein25on Oct 23, 2023 10:36am
219 Views
Post# 35696179

RE:RE:RE:RE:RE:Here we go again

RE:RE:RE:RE:RE:Here we go again NOtaPOOp--- no need to apologize to Foxx. 

It's hard to tell if this amounts to further delay. Roger does indicate at the end of his quote that the central pathology laboratory validation (part of the amendment granteed by HC) will be used for pre-BTD submission. I suspect they already have been tracking down the folks who made it past 450 as either CR or IR to see how they are doing now. Presumably they have been doing this after speaking to FDA in the pre-BTD phone call. If this means we need FDA to sign off on the amendment too...others might know.

What does seem clear to me is that when the time comes for AA submission, we likely will be in a much stronger position as a result of the changes made now to the trial. That's a huge win for us now.
<< Previous
Bullboard Posts
Next >>